• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Citrus Support for the Blood Glucose-Immune System Connection

    A Glance At The Eye Health Market

    The Value of Vitamin D Testing

    A Growing Need for Mineral Supplementation

    More Than Just A Trend: Supplements Embedded in Consumer Health Regimens
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet

    Refined Grains Linked to Heart Attack Risk, Early Death

    Kappa Bioscience Extends Research Partnership For COVID-19 Research

    New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet

    Refined Grains Linked to Heart Attack Risk, Early Death

    Kappa Bioscience Extends Research Partnership For COVID-19 Research

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula

    JRF Technology Debuts Elderberry Oral Film Strip
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet

    Refined Grains Linked to Heart Attack Risk, Early Death

    Kappa Bioscience Extends Research Partnership For COVID-19 Research

    New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers

    GMP Laboratories of America, Inc.: Addressing Industry Challenges for 25 Years
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet

    Refined Grains Linked to Heart Attack Risk, Early Death

    Kappa Bioscience Extends Research Partnership For COVID-19 Research

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula

    Researchers Connect Gut Microbiome to Healthy Aging
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Verdure Sciences

    AIDP

    KLK OLEO - Davos Life Science

    Indena USA, Inc.

    Chenland Nutritionals Inc.
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Aiya America (Matcha by Aiya)

    KLK OLEO - Davos Life Science

    Indena USA, Inc.

    Verdure Sciences

    Vesta Nutra
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    In the Post-Election Lull, Cultivate Clinical Allies

    Regulatory actions taken over the last six months could have lasting impact on the future of integrative medicine.

    In the Post-Election Lull, Cultivate Clinical Allies
    Related CONTENT
    • Preliminary Research Suggests Osteoarthritis Benefits for Herbal Formula JointAlive
    • Schrader-Griffith Bill to Regulate CBD Re-Introduced to 117th Congress
    • Chenland Nutritionals — Pursuing Wellness Beyond Traditional Medicine
    • An Interview with Michael Bentley, President, SierraSIl
    • Premier Joint Support Solution with Clinically-Proven Formula
    Erik Goldman, Holistic Primary Care12.05.16
    Whatever else you might think about Donald Trump’s presidential victory, and whatever moves the Republicans might make toward repealing the Affordable Care Act, it’s a safe bet that regulating the dietary supplement industry won’t be high on the new administration’s to-do list.
     
    No doubt a Republican-controlled Congress is giving many in our industry cause to breathe a deep sigh of relief.
     
    But nobody should get too comfortable. The spate of federal regulatory moves over the last six months could have significant impact on the practitioner channel as well as on the practice of holistic, functional and integrative medicine in the coming years.
     
    While none of these actions represent a direct threat to practice freedom or supplement access, they set precedents that could greatly limit access to dietary supplements and other foundational tools in the practice of holistic and functional medicine.
     
    The FDA’s revisions to its New Dietary Ingredient (NDI) notification process, published in August, received widespread coverage in our industry media. If implemented as written, the revised NDI process would “pharmaceutical-ize” supplements, potentially forcing many existing products off the market, and stifling innovation in the field.
     
    Shortly after issuing the NDI guidelines, the FDA eliminated vinpocetine—a vasodilator compound derived from Vinca—from its list of acceptable supplement ingredients. The move sets a precedent for the quiet “disappearance” of other botanicals.
     
    And then in September, the Drug Enforcement Agency came very close to banning and criminalizing Kratom (Mitragyna speciosa), a southeast Asian herb many chronic pain patients have found to be a safer, more effective alternative to prescription pain medications.
     
    Meanwhile, the Federal Trade Commission has moved to squelch brain-training and cognitive strengthening exercise systems—a development that has no direct bearing on supplements, but does represent a relevant lesson from a parallel universe.
     
    It is anyone’s guess how the Trump administration will deal with FDA, FTC and other federal regulatory agencies. But nobody should be resting easy. In the inevitable regulatory lull that will follow the presidential transition, our industry has an opportunity to cultivate clinical as well as political allies.
     
    NDI System: Protecting Whom?
    The FDA’s revised New Dietary Ingredient (NDI) Notification guidance has significance for anyone in the industry. If implemented as written, the guidelines have potential to change the regulatory status of thousands of products.
     
    The basis for the NDI notification system is in the Dietary Supplement Health and Education Act (DSHEA) of 1994, which set up the regulatory framework governing the supplement industry.
     
    Under the law, companies bringing novel supplement ingredients to market are supposed to notify the FDA of that intention. The agency would then review safety data supporting the ingredients prior to their entry into the market.
     
    FDA sees NDI notification as a preventive control to protect consumers from exposure to ingredients of unknown safety. But in the two decades since passage of DSHEA, FDA’s definition of what counts as  “novel” has been vague, as have the standards of evidence needed to prove safety.
     
    As a result, industry compliance and regulatory enforcement have both been slack. According to FDA, there are 55,600 supplement products already on the U.S. market, and more than 5,000 new ones emerging every year. But the agency only receives an average of 38 NDI notifications per year.
     
    The NDI process, as detailed in the August guidelines, will allegedly grandfather any naturally occurring compound provably present in the food supply as a dietary ingredient or dietary supplement ingredient prior to October 1994. New ingredients or formulations introduced after 1994 would be reclassified as an NDI and subject to review.
     
    How ‘Old’ Becomes ‘New’
    This sounds reasonable, but there’s a catch: Since there was no official definition of “dietary supplement” or “dietary ingredient” prior to DSHEA in 1994, it could be hard to prove something was in fact a dietary ingredient in the pre-DSHEA era.
     
    Under the new guidelines, many old ingredients could be reclassified as NDIs—and subject to costly review—if any aspect of the formulation has changed.
     
    Several industry thought leaders have pointed out that any change in a supplement’s formulation, manufacturing process, dosage or delivery form could reclassify an ingredient as an NDI, and require it to undergo a quasi-pharma level of safety review.
     
    One could argue, for example, that turmeric is a naturally occurring substance that’s been part of the food supply for centuries prior to passage of DSHEA.
     
    But a highly purified isolate of curcumin extracted from turmeric? That might not fly under the FDA’s new proposed rules, meaning that any or all curcumin supplements could be pulled from the market until FDA completes exhaustive safety reviews.
     
    Some medical people might consider the increased safety scrutiny to be a good thing. There’s no question there are holes in existing supplement regulation. But given how widely supplements are used—a recent estimate published in JAMA indicated that 52% of all U.S. adults use these products regularly—the incidence of supplement-related adverse events remains quite low.
     
    The United Natural Products Alliance estimated that compliance with the new rules as written could cost manufacturers somewhere between $2 billion and $6 billion annually, and will strongly discourage companies from developing new formulations or introducing new ingredients.
     
    There will be heavy costs on the federal side as well. Unless Congress markedly augments the FDA’s budget, the agency won’t likely have the resources to handle the surge of NDI notifications the new guidelines would generate.
     
    Arrivaderci, Cousin Vinnie
    For a foretaste of life under the new NDI rules, consider vinpocetine.
     
    Just a few weeks after releasing the NDI guidance, the FDA announced an intention to deem this vasodilator compound—originally found in the Periwinkle plant (Vinca minor) and sold for decades in supplements for cognitive support and weight loss—no longer permissible in supplement products.
     
    This is despite the fact that there are five NDI notifications for vinpocetine in the FDA’s database. In each of these five cases, FDA ruled that the ingredient is safe based on then-available data. There have been no surges in vinpocetine related side effects in recent years that would prompt such sudden, rapid action.
     
    The move might stem from a push by Missouri Senator Claire McCaskill, of the Senate’s Special Committee on Aging, who in 2015 called on the FDA to suspend sales of vinpocetine-containing supplements.
     
    Or it may have to do with the fact that back in 1981, a drug-maker filed an Investigational New Drug application for vinpocetine and conducted several clinical trials, though no prescription vinpocetine ever came to market in the U.S. Vinpocetine is sold as the drug Cavinton in Europe.
     
    If something comes to market first as a supplement it may be later developed into a pharmaceutical—think prescription fish oils like Lovaza. But if a compound is first developed as a drug, it can never be a supplement.
     
    The FDA’s—and Sen. McCaskill’s—other big argument against vinpocetine is that most products on the market contain synthetic forms of the compound, not extracts from plants, meaning that they are not technically “naturally-occurring forms.”
     
    That’s fair enough, from the viewpoint that natural products should contain naturally occurring ingredients. 
     
    But if the FDA applies this logic across the industry, a vast number of products will face imminent ban, because synthetic forms of vitamins, and “bio-identical” botanicals are ubiquitous.
     
    Rather than wanton banishing of ingredients, a more meaningful approach might be to require manufacturers to disclose the presence of synthetic ingredients on product labels, giving consumers freedom of choice. But given how the GMO labeling effort panned out, this is not likely to happen.
     
    DEA Bans—Then Un-Bans—Kratom
    In September, the Drug Enforcement Agency invoked its emergency powers to classify the herb Kratom as a Schedule 1 drug of abuse.
     
    This Asian herb, which many Americans had barely even heard of prior to the DEA’s move, has been growing in popularity in recent years among people with chronic pain, PTSD and anxiety.
     
    Indigenous to Malaysia, New Guinea and other parts of Southeast Asia, Kratom (Mitragyna speciosa) is a tropical evergreen tree, and a distant relative of coffee. It has a history of traditional use for chronic pain in Asian countries.
     
    The scope of use in the U.S. is not clear, but it has been on the rise in the wake of the opioid addiction epidemic and the medical community’s growing reluctance to prescribe opioids.
     
    Though not technically an opiate, Kratom contains alkaloids with both stimulant and depressant effects mediated primarily through monoaminergic and opioid receptors in the central nervous system. Some chronic pain patients say Kratom is a life-saver.
     
    The DEA says the herb—which people take in pill or capsule form, or as a tea—is dangerous, citing risks of addiction, overdose, respiratory depression and seizures.
     
    To make its case for the ban, DEA points to rising hospitalization rates, and a whopping 15 Kratom-associated deaths in the U.S. between 2014 and 2016. That’s about 7 per year, right up there with lightning strikes, shark attacks, and assaults by people in clown suits.
     
    CDC data show only 660 Kratom-related reports to poison control centers between 2010 and 2015, for an average of 132 per year. One quarter of these were mild and non-life threatening, and 42% were only moderately serious. While 49 of these cases (7%) were life threatening, a few of these were in people taking prescription drugs in addition to Kratom. Whether the actual adverse events were from Kratom itself or from contaminants and adulterants, we will never know.
     
    Overall, the stats are a fairly flimsy basis for sudden criminalization of a potentially useful herb, at a time when chronic pain is rampant, prescription opiate addiction is out of hand, and side-effects from anti-inflammatory drugs cost the nation $368 million or more every year.
     
    DEA’s attempt to ban Kratom triggered a massive public outcry—well, relatively massive, given the obscurity of the plant.
     
    More than 130,000 citizens—including many military vets and chronic pain patients—signed a petition to block the ban. In mid-September, hundreds of Kratom advocates marched in front of the White House.
     
    A surprisingly bipartisan coalition of more than 50 legislators sent a joint letter urging the DEA to stand-down. In mid-October the DEA said it was scrapping the ban, and instead opening a public comment and review period, while awaiting an FDA analysis of Kratom, prior to making a final determination about how to regulate the herb.
     
    Of note, FDA is currently reviewing an intravenous opioid drug called Oliceridine (Trevena) that has some biochemical similarities to compounds found in Kratom. Trevena already has several successful phase II Oliceridine trials in its portfolio. Two phase III studies are in progress.
     
    FTC Clampdown on Brain Training
    The supplement industry wasn’t the only sector to feel increased regulatory heat of late. The Federal Trade Commission has been going after companies that make brain-training games. 
     
    Earlier this year, FTC charged Lumos Labs—the San Francisco company that markets the popular Lumosity cognitive fitness system—with making false and misleading claims about the system’s ability to improve IQ, stave off age-related cognitive decline, and restore brain function following stroke.
     
    At peak last year, Lumosity had engaged roughly 70 million people, many of whom were paying $15 per month for access to the system’s vast array of games designed to stimulate and strengthen various cognitive skills.
     
    FTC argued that Lumos used shoddy science to peddle false hope and pander to fears of dementia. The company settled for $2 million, which will be used to refund more than 13,000 customer grievances.
     
    In fact, Lumosity has been the subject of a number of studies. While outcomes have been mixed, there are several trials showing increased alertness, enhanced neurocognitive plasticity, improved visual attention, and improved function across several cognitive parameters. That said, there is no definitive evidence that Lumosity—or any other brain game system—can prevent dementia.
     
    Financially, Lumos’ settlement is minute. But the impact has been far-reaching. In effect, the FTC squelched the company.
     
    According to a recent article on the STATNews website, new downloads of Lumosity’s iPhone app dropped from a peak of 2 million per month in 2013 to less than 400,000 per month this past summer.
     
    Lumos may have exaggerated the science supporting its system, but given the ubiquity of dementia, the absence of any meaningful conventional therapy, and the absolute safety of brain training, the FTC’s action seems very misguided. 
     
    By and large, practicing clinicians have not been involved in shaping regulatory policy. Nor do they volunteer to come to bat for the industry when the heat comes down. Functional and holistic practitioners were essentially mum about the new NDI guidelines, the nixing of vinpocetine and the Kratom ban. The vast majority of these practitioners don’t know the first thing about these actions.
     
    Holistic Primary Care’s 2016 practitioner survey showed that 57% of practitioners don’t even know what DHSEA is—and these were heavy supplement-users.
     
    But practitioners of natural medicine share considerable common cause with the companies that make and market the nutritional and botanical products they use in their practices. They—and their patients—have much to lose if beneficial products are forced out of the market by sudden regulatory changes.
     
    Leaders in the practitioner channel would be wise to invest time, energy and attention in cultivating and nurturing stronger and more active relationships with leading practitioners and with the professional organizations. Sooner or later, we’ll need them.
     

    Erik Goldman
    Holistic Primary Care

    Erik Goldman is co-founder and editor of Holistic Primary Care: News for Health & Healing, a quarterly medical publication reaching about 60,000 physicians and other heathcare professionals nationwide. He is also co-producer of the Practitioner Channel Forum, an annual executive level gathering focused on challenges and opportunities in the health practitioner channel. For more information: www.TPCForum.com.
    Related Searches
    • Regulations
    • Cognitive Function
    • Quality & Safety
    • Healthcare Trends
    Related Knowledge Center
    • Cognitive Function
    • Healthcare Trends
    • Quality & Safety
    Suggested For You
    Preliminary Research Suggests Osteoarthritis Benefits for Herbal Formula JointAlive Preliminary Research Suggests Osteoarthritis Benefits for Herbal Formula JointAlive
    Schrader-Griffith Bill to Regulate CBD Re-Introduced to 117th Congress Schrader-Griffith Bill to Regulate CBD Re-Introduced to 117th Congress
    Chenland Nutritionals — Pursuing Wellness Beyond Traditional Medicine Chenland Nutritionals — Pursuing Wellness Beyond Traditional Medicine
    An Interview with Michael Bentley, President, SierraSIl An Interview with Michael Bentley, President, SierraSIl
    Premier Joint Support Solution with Clinically-Proven Formula Premier Joint Support Solution with Clinically-Proven Formula
    Chenland Nutritionals Files NDl Notification for Joint Health Formula  Chenland Nutritionals Files NDl Notification for Joint Health Formula
    FDA’s Steven Tave Discusses Bridging Gaps Between Regulation and Enforcement FDA’s Steven Tave Discusses Bridging Gaps Between Regulation and Enforcement
    Are We at The End of the ‘Integrative Medicine’ Era? Are We at The End of the ‘Integrative Medicine’ Era?
    UNPA Offering New GMP Training Course June 27-28 UNPA Offering New GMP Training Course June 27-28
    Dietary Supplement Associations to Host May 10 Seminar Dietary Supplement Associations to Host May 10 Seminar
    Political Disruption Presents  Opportunity for Industry Political Disruption Presents Opportunity for Industry
    AHPA: FDA Acknowledged About 25% of Recent NDI Notifications With No Objection AHPA: FDA Acknowledged About 25% of Recent NDI Notifications With No Objection
    Advanced Orthomolecular Research Debuts Curcumin Ultra Advanced Orthomolecular Research Debuts Curcumin Ultra
    Healthcare Under Trump: What Can the Practitioner Channel Expect? Healthcare Under Trump: What Can the Practitioner Channel Expect?
    Establishing Specifications as Required by Dietary Supplement cGMPs Establishing Specifications as Required by Dietary Supplement cGMPs

    Related Columns

    • Dietary Supplements | Healthcare Trends | Medical Nutrition | Regulations
      The Off-Label On Ramp

      The Off-Label On Ramp

      With an expanding base of clinical research supporting nutritional interventions, off label use of dietary supplements and medical foods is likely to grow.
      By Gregory Stephens, Windrose Partners, and Sheila Campbell, PhD, RD 01.19.21

    • Dietary Supplements | Healthcare Trends | Immune Function | Regulations
      ‘Follow the Science’ Often Misses the Mark with Nutrition

      ‘Follow the Science’ Often Misses the Mark with Nutrition

      The mantra too often ignores common sense approaches to improving health and quality of life.
      By Todd Harrison, Venable 01.19.21

    • Dietary Supplements | Herbs & Botanicals | Regulations | World Markets
      CBD in Europe: News from the Front

      CBD in Europe: News from the Front

      A recent decision by the Court of Justice of the European Union has restored CBD’s status, and with it, the prospects of the entire industry.
      By Joerg Gruenwald, analyze & realize ag 01.19.21


    • Cardiovascular Health | Herbs & Botanicals | Immune Function | Research | Weight Management/Weight Loss
      Botanical Research: Botanicals & Immunity, Kava Challenges, Turmeric Therapeutics and More

      Botanical Research: Botanicals & Immunity, Kava Challenges, Turmeric Therapeutics and More

      AHPA compiles recent research on botanicals and plant compounds published in peer-reviewed journals.
      By Holly Johnson, PhD, American Herbal Products Association (AHPA) 01.19.21

    • Delivery & Dosage Technologies | Dietary Supplements | Herbs & Botanicals | Quality & Safety
      The Advantages of Organic, Broad Spectrum Hemp

      The Advantages of Organic, Broad Spectrum Hemp

      Mike Hennesy, Wana Brands, discusses the company’s new gummies, innovation, and continuing market evolution.
      By Sheldon Baker 12.04.20

    • Dietary Supplements | Regulations
      Insurance Rates Have Been at an All-Time Low, But a Hard Market is Coming

      Insurance Rates Have Been at an All-Time Low, But a Hard Market is Coming

      Companies can be prepared by being thorough and transparent while going through insurance policy renewals.
      By Chris Morey, Bolton & Company 12.04.20


    • Dietary Supplements | Regulations
      A Business Perspective on Protecting Confidential Information: The NDA

      A Business Perspective on Protecting Confidential Information: The NDA

      Along with taking precautions in providing access to confidential information, a non-disclosure agreement can be a great way to protect your business.
      By Gregory Stephens, Windrose Partners 11.09.20

    • Dietary Supplements | Healthcare Trends | Immune Function | Regulations | Research | Vitamins
      Using All the Tools to Improve Public Health

      Using All the Tools to Improve Public Health

      Industry needs to make a stand in compelling authorities to communicate the value of nutrition and dietary supplementation.
      By Todd Harrison, Venable 11.09.20

    • Dietary Supplements | Regulations | World Markets
      Regulation Changes Calculus for Substance-Based Medical Devices

      Regulation Changes Calculus for Substance-Based Medical Devices

      The new regulation introduces more specific requirements for the technical documentation of this class of products.
      By Joerg Gruenwald, analyze & realize ag 11.09.20


    • Cognitive Function | Herbs & Botanicals | Mood Health & Sleep | Probiotics & Prebiotics | Research | Sports Nutrition
      Botanical Research: Oral Creatine Monohydrate, Probiotics & Antimicrobial Proteins, Mushrooms & More

      Botanical Research: Oral Creatine Monohydrate, Probiotics & Antimicrobial Proteins, Mushrooms & More

      AHPA compiles recent research on botanicals and plant compounds published in peer-reviewed journals.
      By Holly Johnson, PhD, American Herbal Products Association (AHPA) 11.09.20

    • Dietary Supplements | Healthcare Trends | Immune Function | Regulations
      Federal Regulators Slam Doctors for COVID-Related Communications

      Federal Regulators Slam Doctors for COVID-Related Communications

      Some practitioners were not selling or promoting products, they were simply suggesting certain natural substances might offer benefits in improving resilience.
      By Erik Goldman, Holistic Primary Care 10.01.20

    • Delivery & Dosage Technologies | Dietary Supplements | Healthcare Trends | Herbs & Botanicals | Pet Nutraceuticals
      CBD Dog Health and Fire Flake Farm: Holistic Healing for Furry Friends

      CBD Dog Health and Fire Flake Farm: Holistic Healing for Furry Friends

      Angela Ardolino is a certified cannabis specialist and holistic pet expert who has been caring for animals for over 20 years.
      By Sheldon Baker 10.01.20


    • Dietary Supplements | Regulations
      Nuance Claims? The Red Flags Around False Advertising, Intellectual Property & Mislabeling

      Nuance Claims? The Red Flags Around False Advertising, Intellectual Property & Mislabeling

      If you are a product formulator, label designer, or manufacturing facility, an Errors and Omissions policy is worth exploring.
      By Chris Morey, Bolton & Company 10.01.20

    • Dietary Supplements | Healthcare Trends | Research
      Spotlight on Clinical Research in the COVID-19 Era

      Spotlight on Clinical Research in the COVID-19 Era

      Discerning high quality research evidence from speculation and marketing hype is more important in today’s climate.
      By Greg Stephens, Windrose Partners, & Sheila Campbell, PhD, RD 09.08.20

    • Immune Function | Regulations | Research | Vitamins
      Nutritional Status Has Critical Implications for Public Health

      Nutritional Status Has Critical Implications for Public Health

      Vitamin D, N-acetyl cysteine, and quercetin may have important roles to play in this pandemic.
      By Todd Harrison, Venable 09.08.20

    Trending
    • Nestlé To Sell North American Water Brands
    • House Resolution Calls For CDC And FDA To Back Vitamin D For COVID-19
    • Innova: Top Trends In Dairy Focus On Holistic Benefits
    • Carlson Launches New Grade Of Astaxanthin Gummies With Astaferm
    • Omega-3s Recommended In Australian Pregnancy Guidelines Update
    Breaking News
    • Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    • Refined Grains Linked to Heart Attack Risk, Early Death
    • Kappa Bioscience Extends Research Partnership For COVID-19 Research
    • New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers
    • Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    View Breaking News >
    CURRENT ISSUE

    Jan/Feb 2021

    • Modern Snacking: Where Health & Indulgence Converge
    • More Than Just A Trend: Supplements Embedded in Consumer Health Regimens
    • A Growing Need for Mineral Supplementation
    • The Value of Vitamin D Testing
    • A Glance At The Eye Health Market
    • Citrus Support for the Blood Glucose-Immune System Connection
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    Cosmetic Chemical Sales To Post CAGR 5.8% To 2025
    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login